Performance data is updated to 30 April 2026.
VanEck Global Healthcare Leaders ETF
Our global healthcare ETF, HLTH gives investors exposure to a diversified portfolio of the largest international companies from the global healthcare sector. Our global healthcare ETF aims to provide investment returns, before fees and other costs, which track the performance of the Index.
Performance (% return)
Investment Focus
Themes
Exposure Regions
Portfolio Breakdown
| Symbol | Company Name | % assets |
|---|---|---|
| SOBI SS | Swedish Orphan Biovitrum Ab | 2.80% |
| GMED US | Globus Medical Inc | 2.76% |
| MRK US | Merck & Co Inc | 2.72% |
| REGN US | Regeneron Pharmaceuticals Inc | 2.59% |
| LLY US | Eli Lilly & Co | 2.58% |
| AMGN US | Amgen Inc | 2.57% |
| BIIB US | Biogen Inc | 2.56% |
| JNJ US | Johnson & Johnson | 2.49% |
| BMY US | Bristol-Myers Squibb Co | 2.48% |
| INCY US | Incyte Corp | 2.41% |
| Sector | % assets |
|---|---|
| United States | 65.3% |
| Japan | 8.9% |
| Denmark | 7.9% |
| South Korea | 5.6% |
| Switzerland | 3.7% |
| Sweden | 2.3% |
| United Kingdom | 2.2% |
| Belgium | 2.2% |
| Finland | 1.8% |
| Other/Cash | 0.1% |
Similar ETFs
| Stock | Name | 1 Year % |
|---|---|---|
| DRUG | BetaShares Global Healthcare Currency Hedged ETF | +4.52% |
| CURE | S&P Biotech ETF | +38.76% |
Disclaimer
The information provided on ReviewETF.com.au is intended for general information and comparison purposes only. It is compiled and presented on a best-endeavours basis from publicly available sources, but we do not guarantee its accuracy, completeness, timeliness, or suitability for any particular purpose.
No content on this website constitutes financial advice, investment recommendation, solicitation, or an offer to buy or sell any securities. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of capital.
The point of truth for any ETF is always the official product disclosure statement (PDS), website, and announcements from the ETF issuer/provider (e.g., Vanguard, BetaShares, iShares, VanEck, etc.). We link directly to these primary sources on each individual ETF page wherever possible—please verify all details there before making any decisions.
ReviewETF.com.au, its owner (Joshua), and any associated entities disclaim all liability for any loss or damage arising from the use of, or reliance on, information contained on this site. Users should seek independent professional financial advice tailored to their personal circumstances.
This website may contain links to third-party sites; we are not responsible for their content or privacy practices.
Last updated: January 2026
